EF Hutton Maintains Buy on Nemaura Medical, Lowers Price Target to $4
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Constantine Davides maintains a 'Buy' rating on Nemaura Medical (NASDAQ:NMRD) but has lowered the price target from $6 to $4.
July 17, 2023 | 8:24 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
EF Hutton maintains a 'Buy' rating on Nemaura Medical but lowers the price target from $6 to $4.
The news is directly related to Nemaura Medical. While the 'Buy' rating is maintained, the lowering of the price target could indicate a potential decrease in the short-term stock price. However, the overall impact is neutral as the 'Buy' rating suggests that the stock is still expected to perform well in the long run.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100